

TITLE OF CLINICAL TRIAL	MCC#	STAGE	PRIOR TRT Y/N	PRINCIPAL INVESTIGATOR	CLINICAL TRIAL COORDINATOR
Total Lung Care (TLC) Study: Epidemiological study	15768	All	N/A	Dr. Matthew Schabath	Kristen Jonathan (813) 745-8395
Non-Small Cell Lung Cancer (NSCLC) Mutation Specific Trials					
Epidermal Growth Factor Receptor (EGFR) Mutation					
Randomized, Double-Blind, Phase II Study of erlotinib (Tarceva®) in combination with OSI-906 or Placebo in Advanced NSCLC with Activating Epidermal Growth Factor Receptor (EGFR) Mutation	16563	IIIB-IV	N	Dr. Alberto Chiappori	Tim Estrella (813)745-3685
KRAS Mutation					
Phase IB/II Study of IPI-504 in Combination with Everolimus in Patients with KRAS Mutant NSCLC	16616	IIIB or IV	Y	Dr. Jhanelle Gray	Melissa Joiner (813)745-3685
Non-Small Cell Lung Cancer (NSCLC)					
Randomized Phase III Trial of Adjuvant Chemotherapy w/ or w/o Bevacizumab	15573	Resected IB (>4 cm)-IIIA	N	Dr. Mary Pinder-Schenck	Aaron Becker (813)745-4679
Phase I Study of Bendamustine with Concurrent Whole Brain Radiation Therapy in Patients with Brain Metastases from Solid Tumors	15690	IV	Y	Dr. Edward Pan	Pam Smith (813) 745-3951
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage Centrally Located NSCLC in Medically Inoperable Patients	15786	I	N	Dr. Thomas Dilling	Bonnie Sauder (813) 745-3574
Phase I Study of the HDAC Inhibitor Vorinostat with chemotherapy and radiation therapy for locally advanced NSCLC	16254	IIIA-IIIB	N	Dr. Mary Pinder-Schenck	Melissa Joiner (813)745-1896
Randomized Phase II Study of Imetelstat as Maintenance Therapy after Initial Chemotherapy for Advanced NSCLC	16531	IV	Y	Dr. Alberto Chiappori	Amanda Sweeney (813) 745-1457
Prospective, Multi-center Study, to Evaluate the Efficacy and Safety a PET Imaging Radiotracer in Early Detection of Response of Non-Hematological Tumors to Concurrent Chemoradiotherapy	16536	II-III	Y	Dr. Michael Tomblyn	Bonnie Sauder (813) 745-3574
Phase 1, Open-label, Multi-center, Multi-dose, Dose-escalation Study of BMS-936558 (MDX-1106) in Selected Advanced or Recurrent Malignancies	16623	IV	Y	Dr. Scott Antonia	Aaron Becker (813)745-4679
Small Cell Lung Cancer (SCLC)					
Randomized Phase II Trial Using Dendritic Cells Transduced with an Adenoviral Vector Containing the p53 Gene to Immunize Patients in Combination with Chemotherapy w/ or w/o All Trans Retinoic Acid	15206	Extensive	Y	Dr. Alberto Chiappori	Sierra Theodore (813) 745-3620
Ad. P53 DC Vaccine &1-Mt for SCLC	16025	Limited or Extensive	Y	Dr. Hatem Soliman	Mira Lacevic (813) 745-8304

Updated October 18, 2011